Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) was the target of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,130,000 shares, a growth of 7.6% from the October 15th total of 1,050,000 shares. Based on an average trading volume of 163,000 shares, the days-to-cover ratio is presently 6.9 days. Approximately 2.7% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. BTIG Research raised their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday, October 18th. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price target on shares of Aura Biosciences in a research note on Thursday. Scotiabank increased their price objective on Aura Biosciences from $20.00 to $23.00 and gave the stock a "sector outperform" rating in a research note on Friday, October 18th. JMP Securities lifted their price objective on Aura Biosciences from $19.00 to $23.00 and gave the company a "market outperform" rating in a report on Friday, September 13th. Finally, Evercore ISI raised shares of Aura Biosciences to a "strong-buy" rating in a report on Monday, September 16th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $23.00.

Insider Activity at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 24,992 shares of the business's stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $12.04, for a total transaction of $300,903.68. Following the sale, the insider now directly owns 329,847 shares in the company, valued at approximately $3,971,357.88. The trade was a 7.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CTO Mark Plavsic sold 7,383 shares of the company's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the transaction, the chief technology officer now owns 121,132 shares of the company's stock, valued at $1,193,150.20. The trade was a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 67,259 shares of company stock worth $780,699 in the last ninety days. 5.40% of the stock is currently owned by insiders.

Institutional Trading of Aura Biosciences

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in Aura Biosciences by 4.1% in the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock valued at $8,990,000 after acquiring an additional 39,379 shares during the last quarter. Barclays PLC boosted its stake in shares of Aura Biosciences by 256.5% in the 3rd quarter. Barclays PLC now owns 61,010 shares of the company's stock valued at $544,000 after purchasing an additional 43,897 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Aura Biosciences during the 3rd quarter worth approximately $1,037,000. State Street Corp raised its stake in shares of Aura Biosciences by 3.7% during the third quarter. State Street Corp now owns 754,803 shares of the company's stock worth $6,725,000 after buying an additional 26,841 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Aura Biosciences by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company's stock valued at $1,233,000 after buying an additional 3,612 shares during the period. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Stock Down 5.0 %

AURA traded down $0.50 during trading on Friday, hitting $9.47. The company's stock had a trading volume of 284,021 shares, compared to its average volume of 231,682. The firm's 50 day moving average price is $9.82 and its two-hundred day moving average price is $8.54. The stock has a market capitalization of $473.03 million, a price-to-earnings ratio of -5.47 and a beta of 0.33. Aura Biosciences has a 12 month low of $6.63 and a 12 month high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.02. On average, sell-side analysts forecast that Aura Biosciences will post -1.69 earnings per share for the current year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.